Stanovení intracelulární koncentrace imatinibu u CML pacientů
| Title in English | Determination of intracellular imatinib concentration in CML patients |
|---|---|
| Authors | |
| Year of publication | 2010 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | Nowadays, imatinib (IMA), the BCR-ABL tyrosinkinase inhibitor, is first line therapy of chronic myeloid leukemia (CML). In the case of some patients, the therapy by IMA fails or leads to suboptimal response. Information about IMA distribution , including IMA intracellular concentration in selected cell population, may help to elucidate the individual therapy outcome. Preparation of isolated cells and LC-MS/MS method for IMA determination was optimized. Also influence of selected techniques for cell population isolation (K562 cell lines in vitro cultivated with IMA) on observed IMA intracellular concentration was tested. Significant decrease of IMA intracellular concentration was observed compared with PBS wash when isolation of white blood cells was performed using erythrocyte lysis. Isolation of mononuclear cells using Histopaque and Vacutainer test tube give comparable results with PBS wash. |
| Related projects: |